This week in therapeutics




Licensing status

Publication and contact information

Infectious disease


b-Site APP-cleaving enzyme 1 (BACE1)

Cell culture studies suggest inhibiting the interaction between HCV and transferrin receptor could help prevent infection. In human hepatocarcinoma cells, small interfering RNA-, antibody- or small molecule-mediated inhibition of transferrin receptor decreased viral infection compared with no inhibition. In the cells, an antibody against the transferrin receptor decreased infection by engineered HCV particles compared with other engineered viral particles. Next steps include mapping the interaction between the transferrin receptor and HCV.
Roche has an anti-BACE1 and anti-transferrin receptor antibody in preclinical testing to treat Alzheimer's disease (AD).

SciBX 6(27); doi:10.1038/scibx.2013.686
Published online July 18, 2013

Unpatented; licensing status not applicable

Martin, D.N. & Uprichard, S.L. Proc. Natl. Acad. Sci. USA; published online
June 10, 2013;
Contact: Susan L. Uprichard, Loyola University Medical Center, Maywood, Ill.